The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response

被引:5
|
作者
Mandish, Steven F. [1 ]
Gaskins, Jeremy T. [2 ]
Yusuf, Mehran B. [1 ]
Amer, Yomna M. [3 ]
Eldredge-Hindy, Harriet [1 ]
机构
[1] Univ Louisville Hosp, Dept Radiat Oncol, Louisville, KY USA
[2] Univ Louisville, Dept Bioinformat & Biostat, Louisville, KY 40202 USA
[3] Univ Louisville, Sch Med, Louisville, KY 40202 USA
关键词
RADIATION-THERAPY; CANCER; STAGE; IRRADIATION; DISTANCE; OUTCOMES; IMPACT; TRASTUZUMAB; POPULATION; CARCINOMA;
D O I
10.1080/0284186X.2020.1797161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective(s) Neoadjuvant chemotherapy (NAC) is a standard of care for locally advanced breast cancers. Adjuvant radiotherapy (RT) after NAC is an area of active research. We hypothesize overall survival (OS) is not altered by omitting RT in women with a pathologic complete response (pCR) to NAC after breast conserving survery (BCS). Methods Patients from the National Cancer Database who underwent NAC, BCS, and had a pCR were included. Inflammatory disease, <6 months follow up, and unknown variables were excluded. Descriptive statistics characterized the retained cohort. Logistic regression analyzed the influence of variables on the rate of RT omission. Cox proportional hazard modeling analyzed the influence of prognostic variables on OS. Results Of 5383 women included, 364 (7%) omitted RT. 5-year OS was 94.1% with RT, 93% without. RT omission was most likely in women >70yo (adjusted OR2.4, 95%CI 1.58-3.65,p < .0001;reference 40-49 yo), Hispanic (AOR 1.73, 95%CI 1.19-2.52,p = .0044; reference non-Hispanic), >= 20 miles from treatment facility (20-49 miles; AOR 1.45, 95%CI 1.09-1.93,p = .0109: >50 miles; AOR 2.02, 95%CI 1.42-2.87,p < .0001;reference 0-19 miles), grade 1 (AOR 4.29, 95%CI 2.16-8.51,p < .0001; reference grade 3), and clinical T4 disease (AOR 3.17, 95%CI 1.74-5.79,p = .0002; reference T0/1). Women >= 60yo (60-69: AHR 2.33, 95%CI 1.41-3.83,p = .0009:70+:AHR 2.4, 95%CI 1.24-4.62,p = .0092; reference 40-49) and with N1 and N3 disease (N1: AHR 1.67, 95% CI 2.28-3.24,p = .0034; N3: AHR3.37,95%CI2.01-5.65,p < .0001) showed increased death. Triple-positive (AHR 0.18, 95%CI 0.07-0.43,p = .0002) and HER2+ patients (AHR 0.44, 95%CI 0.30-0.64,p < .0001) had improved OS compared to triple-negative disease. No survival difference was seen with omission of RT (log-rank test:p = .1783; Cox model AHR 1.33, 95%CI 0.76-2.31,p = .3181). Conclusion Women >= 70, of Hispanic origin, living >= 20 miles from treatment facility, and grade 1 disease were more likely to omit RT. HER2+ patients had favorable OS, while older age and N3 disease were negative prognostic factors. Omitting RT after a pCR to NAC and BCS was not found to affect OS.
引用
收藏
页码:1210 / 1217
页数:8
相关论文
共 50 条
  • [21] Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery
    Woeste, Matthew R.
    Bhutiani, Neal
    Donaldson, Marilyn
    McMasters, Kelly M.
    Ajkay, Nicolas
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (02) : 439 - 445
  • [22] Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer
    不详
    BREAST, 2005, 14 : S32 - S32
  • [23] should radiotherapy be avoided after neoadjuvant chemotherapy in complete response breast cancer?
    Arenas Prat, M.
    Sabater, S.
    Bonet, M.
    Gascon, M.
    Gomez, D.
    Arquez, M.
    Torres, L.
    Gomez, J.
    Amillano, K.
    Mele, M.
    De la Flor, M.
    Rodriguez, E.
    Camps, J.
    Joven, J.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1271 - S1271
  • [24] Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer
    Han, Sehwan
    Kim, Juree
    Sohn, Seungchang
    Kwak, Geum-Hee
    Kim, Ji-Young
    Park, Kyeongmee
    JOURNAL OF SURGICAL ONCOLOGY, 2007, 95 (01) : 45 - 50
  • [25] Adjuvant radiotherapy after breast conserving surgery for breast cancer -: Arbiter
    Kurtz, JM
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (09) : 1082 - 1084
  • [26] Adjuvant radiotherapy after breast conserving surgery for breast cancer -: Pro
    Sauer, R
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (09) : 1073 - 1078
  • [27] Adjuvant radiotherapy after breast conserving surgery for breast cancer -: Contra
    Wallgren, A
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (09) : 1078 - 1082
  • [28] Omission of Adjuvant Chemotherapy in Rectal Cancer Patients with Pathologic Complete Response: a National Analysis
    Morris, Mackenzie C.
    Winer, Leah K.
    Lee, Tiffany C.
    Shah, Shimul A.
    Rafferty, Janice F.
    Paquette, Ian M.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2021, 25 (07) : 1857 - 1865
  • [29] Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    M Tanioka
    C Shimizu
    K Yonemori
    K Yoshimura
    K Tamura
    T Kouno
    M Ando
    N Katsumata
    H Tsuda
    T Kinoshita
    Y Fujiwara
    British Journal of Cancer, 2010, 103 : 297 - 302
  • [30] Predictors of Pathologic Complete Response in Axillary Nodes After Neoadjuvant Chemotherapy for Breast Cancer
    Ahn, Soojin
    Romeiser, Jamie
    O'Hea, Brian
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : 24 - 25